Want to see HK:2268 full AI Analyst Report?
Top Page
WuXi XDC Cayman, Inc.
(2268)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$74.00
▼(-1.99% Downside)
Action:Downgraded
Date:08/26/26
The score is primarily supported by strong financial performance (solid growth, high margins, and low leverage). Offsetting this are a premium valuation (high P/E) and technical indicators showing an extended near-term setup (RSI/Stoch elevated) despite a strong uptrend.
Positive Factors
Revenue Growth
Strong revenue expansion indicates continued demand for the company’s outsourced life-sciences services and increasing customer activity across development and manufacturing programs. Sustained top-line growth can support broader operating scale, customer engagement, and reinvestment in capabilities over the next several quarters.
Negative Factors
Margin Compression
Broad margin compression suggests that costs increased faster than revenue in the latest period, reducing the earnings benefit of scale. If this pattern persists, future revenue growth may translate into less incremental profit and could constrain the company’s ability to reinvest at the same pace.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue expansion indicates continued demand for the company’s outsourced life-sciences services and increasing customer activity across development and manufacturing programs. Sustained top-line growth can support broader operating scale, customer engagement, and reinvestment in capabilities over the next several quarters.
Read all positive factors
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$84.68B
Dividend YieldN/A
Average Volume (3M)4.87M
Price to Earnings (P/E)46.4
Beta (1Y)0.81
Revenue Growth41.52%
EPS Growth17.10%
CountryHK
Employees2,662
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.22
Shares Outstanding1,270,498,300
10 Day Avg. Volume6,027,714
30 Day Avg. Volume4,865,921
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$91.66Price Target Upside21.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.51
Revenue Forecast (FY)HK$8.16B
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
Company Description
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company...
How the Company Makes Money
WuXi XDC Cayman, Inc. generates revenue primarily by providing fee-for-service outsourcing to pharmaceutical and biotechnology customers, charging for work performed under project-based and/or longer-term service agreements. Key revenue streams ge...
WuXi XDC Cayman, Inc. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.89B | 5.94B | 4.05B | 2.12B | 990.42M | 311.13M |
| Gross Profit | 2.52B | 2.14B | 1.24B | 559.56M | 261.08M | 113.49M |
| EBITDA | 2.12B | 1.77B | 1.33B | 425.01M | 156.71M | 78.22M |
| Net Income | 1.54B | 1.48B | 1.07B | 283.54M | 155.73M | 54.93M |
Balance Sheet | ||||||
| Total Assets | 15.52B | 14.44B | 9.12B | 6.74B | 2.50B | 879.75M |
| Cash, Cash Equivalents and Short-Term Investments | 5.73B | 7.47B | 3.97B | 4.05B | 734.97M | 26.32M |
| Total Debt | 531.43M | 879.52M | 496.43M | 2.84M | 77.18M | 24.59M |
| Total Liabilities | 3.95B | 3.71B | 2.48B | 1.28B | 1.02B | 858.87M |
| Stockholders Equity | 11.30B | 10.73B | 6.64B | 5.45B | 1.48B | 20.88M |
Cash Flow | ||||||
| Free Cash Flow | 1.25B | 634.64M | -787.95M | -206.51M | 50.43M | 7.23M |
| Operating Cash Flow | 2.50B | 1.85B | 717.22M | 332.85M | 251.82M | 59.14M |
| Investing Cash Flow | 461.16M | -1.43B | -3.33B | -91.23M | -1.28B | -51.59M |
| Financing Cash Flow | 1.32B | 2.80B | 475.36M | 3.52B | 1.33B | 22.34M |
WuXi XDC Cayman, Inc. Technical Analysis
Negative
75.50
Price Trends
75.66
Negative
65.88
Positive
63.03
Positive
Market Momentum
-2.39
Positive
32.97
Neutral
15.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Negative. The current price of 75.5 is below the 20-day moving average (MA) of 75.98, below the 50-day MA of 75.66, and above the 200-day MA of 63.03, indicating a neutral trend. The MACD of -2.39 indicates Positive momentum. The RSI at 32.97 is Neutral, neither overbought nor oversold. The STOCH value of 15.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2268.
WuXi XDC Cayman, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% | |
72 Outperform | HK$183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% | |
69 Neutral | HK$84.68B | 46.36 | 14.00% | ― | 41.52% | 17.10% | |
58 Neutral | HK$54.78B | 40.79 | 6.66% | 1.44% | 23.95% | 18.73% | |
55 Neutral | HK$42.54B | -76.42 | -2.00% | 0.38% | 16.21% | -82.18% | |
53 Neutral | HK$80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2268
WuXi XDC Cayman, Inc.
66.65
-8.45
-11.25%
HK:2269
Wuxi Biologics (Cayman)
44.48
8.28
22.87%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
37.92
-8.40
-18.14%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
26.98
1.25
4.86%
HK:2359
WuXi AppTec Co., Ltd. Class H
185.40
78.52
73.47%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
103.90
21.34
25.85%
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Grants Restricted Shares to Employees Under 2024 Incentive Scheme
Aug 25, 2026
WuXi XDC Cayman Inc., listed on the Hong Kong Stock Exchange and incorporated in the Cayman Islands, utilizes share incentive schemes to reward employees and align their interests with long-term corporate performance. Operating in the biopharmaceu...
WuXi XDC Delivers Strong Interim Growth but Withholds Interim Dividend
Aug 24, 2026
WuXi XDC Cayman Inc. reported a robust set of interim results for the six months ended June 30, 2026, with group revenue climbing 37.0% year on year to RMB3,701.4 million and gross profit rising 40.6% to RMB1,371.3 million. The gross profit margin...
WuXi XDC to Present 2026 Interim Results via Dual-Language Investor Calls
Aug 24, 2026
WuXi XDC Cayman Inc., a biopharmaceutical services provider listed in Hong Kong, offers contract development and manufacturing solutions to drug developers, with a focus on biologics and innovative therapeutics. Its operations are overseen by a bo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.